MBRX News and Press, Moleculin Biotech Inc. From 04/18/24

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine a...

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties PR Newswire Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against establi...

2024-03-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference PR Newswire Live webcast on Thursday, April 4 th at 4:10 PM ET HOUSTON , March 28, 2024 /...

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity PR Newswire Live webcast with Walter Klemp , Chairman and Chief Executive Officer, on Thursday, March 28 th at 12:00 PM ET HOUSTON , March 27, 2024 /PR...

2024-03-27 09:22:30 ET More on Moleculin Biotech Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotec...

Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML PR Newswire Patent, once issued, will provide composition of matter protection through 2040, with potential for additional term extension Next-generation anthracycline use...

2024-03-25 11:25:19 ET Moleculin Biotech, Inc. (MBRX) Q4 2023 Earnings Conference Call March 25, 2024, 08:30 AM ET Company Participants Jenene Thomas - IR Walter Klemp - Chairman and CEO Paul Waymack - Senior CMO Jonathan Foster - EVP and CFO Conference...

Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial PR Newswire – Annamycin in combination with Cytarabine (AnnAraC) achieves CRc rate of 60% (50% CR) in 2 nd line AML subjects – AnnAraC has potential to fill significant...

2024-03-22 16:16:03 ET More on Moleculin Biotech Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech Read the full article on Seeking Alpha For further det...